对于阿尔茨海默氏症的双重GSK3β/SIRT1调节器:机制,药物发现和未来的前景
Afeez I Kareem1, Erika Kapp1, Jacques Joubert1
1Department of Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Bellville, South Africa.
Frontiers in pharmacology
|October 1, 2025
概括
针对GSK3β和SIRT1提供了一个有希望的阿尔茨海默病 (AD) 治疗的双重方法. 这一策略旨在通过抑制陶和粉样蛋白-β通路来改变疾病,同时促进神经保护.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 缺乏有效的疾病修饰治疗方法,通常是由于单一向药物的限制.
- 糖原合成酶激酶-3β (GSK3β) 在AD中驱动陶过酸化和粉样β (Aβ) 生产.
- 赛尔图因-1 (SIRT1) 是一种神经保护性NAD+依赖性脱乙酶,在AD中具有潜力.
研究的目的:
- 审查阿尔茨海默病中双重抑制GSK3β和激活SIRT1的理由.
- 探索具有双重GSK3β/SIRT1活性的自然化合物作为治疗支架.
- 讨论开发多目标治疗的挑战和进展.
主要方法:
- 对阿尔茨海默病发病过程中GSK3β和SIRT1的机制研究的审查.
- 对具有双重活性的自然化合物 (白醇,柏柏林,甲,奎尔丁) 的分析.
- 检查多目标药物发现方法 (杂交,建模,纳米配方).
主要成果:
- 同时抑制GSK3β和激活SIRT1可以破坏AD病理并增强神经保护.
- 自然化合物显示出作为双重作用药物设计的起点的潜力.
- 药物发现方面的进步提供了克服目标选择性和BBB透等局限性的策略.
结论:
- 双重的GSK3β/SIRT1向策略代表了在AD中神经保护的系统级方法.
- 这种方法对开发更有效的阿尔茨海默氏症疾病修饰疗法充满希望.
- 克服药物输送和选择性方面的挑战对于临床翻译至关重要.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.抑制了GSK3β的发生.通过SIRT1激活.化学信息学 化学信息学具有双重目标的药物设计.多种药理学 多种药理学复星醇是一种复星醇.的过酸化是一种超酸化.更多相关视频
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
7.1K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.4K
相关概念视频
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560